NEW STUDY: The PERL study is currently enrolling participants with type 1 diabetes who may have early signs of kidney problems.

The PERL Study is a clinical trial designed to test whether the medication allopurinol can prevent or slow down kidney disease in people with type 1 diabetes. About 480 people with type 1 diabetes will participate in PERL. The study will last 3 years, and kidney function will be measured periodically to see if this treatment is effective.

What does the PERL study involve?

• Study participants take the study medication (allopurinol or placebo) each day for 3 years.
• At the beginning, middle and end of the study (a total of 4 times), a special test of kidney function, lasting about 4 hours, is performed at a PERL center.
• Other study visits (12 over 3 years) take about 1 hour and can be done at a PERL center (if you live nearby) or at a clinic or office close to your home.
• All study-related procedures and tests are provided at no charge. Participants receive a small payment for their time. Parking and transportation costs may be reimbursed.

You may be eligible for the PERL clinical trial if you:

• Are 18 years or older
• Have been diagnosed with Type 1 (insulin-treated) Diabetes for at least 8 years
• Have had early signs of decreased kidney function on blood and/or urine tests

Allopurinol is a medicine that has been widely used for over 50 years to decrease high uric acid levels in the blood and prevent gout. If the PERL Study can show that allopurinol can also protect kidney function in people with type 1 diabetes, we will have a new, safe and inexpensive tool to prevent or delay kidney failure that can be used at the earliest stages of renal injury. This would be a major advance for the many people with diabetes who are at risk for kidney problems.

For more information, contact us at 1-966-701-3636 or email [email protected].